Compare Tango Therapeutics Inc. (TNGX) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs United States Natural Gas Fund — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while United States Natural Gas Fund trades at $11.16 (market cap $503.45M). The key difference: Tango Therapeutics Inc. is far larger — about 7.4× United States Natural Gas Fund's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and United States Natural Gas Fund for 23 Days on average.
| TNGX | UNG | |
|---|---|---|
Market Cap | $3.74B | $503.45M |
Volume | 3,438,781 | 39,591,120 |
Sector | Health | Commodities - Energy |
52-Week High | $32.90 | $16.90 |
52-Week Low | $7.50 | $9.63 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $2.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
UNG trades at $11.41, up 4.49% today, with a bullish technical signal from moving averages. The company reported $65.15M net income for 2024 despite zero revenue, with strong cash holdings of $593.54M and minimal debt. Recent news highlights natural gas market volatility amid Middle East tensions and record U.S. production.
Outlook is mixed: technical momentum supports near-term gains, but zero revenue and negative cash flow (-$251.70M) raise sustainability concerns. Investment opportunity lies in natural gas market exposure, countered by operational risks and dependence on external factors. Monitor earnings quality and cash flow trends closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
